Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: Implications for cancer risk stratification and biomarker sampling

Rajal B. Shah, James Bentley, Zach Jeffery, Angelo Michael Demarzo

Research output: Contribution to journalArticle

Abstract

ERG and PTEN biomarkers are increasingly being analyzed on prostate core biopsies (NBXs); ERG as a marker of clonality and number of separately arising tumor foci and PTEN for prognostic information. Yet, in patients with multiple biopsy cores positive for cancer (PCa), there is no standardized approach for interrogation of these biomarkers in terms of the number of positive cores to evaluate. A total of 194 NBX cases containing more than one positive core with cancer were evaluated for ERG overexpression and PTEN loss by immunostaining (immunohistochemistry) of all positive cores. ERG overexpression or PTEN loss in at least one cancer core was present in 111 (57%) and 69 (36%) cases respectively. ERG overexpression was significantly associated with PTEN loss (P

Original languageEnglish (US)
Pages (from-to)698-706
Number of pages9
JournalHuman Pathology
Volume46
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Large-Core Needle Biopsy
Prostatic Neoplasms
Biomarkers
Neoplasms
Biopsy
Prostate
Immunohistochemistry

Keywords

  • Biomarkers
  • ERG
  • Heterogeneity
  • Prostate cancer
  • Prostate needle biopsy
  • PTEN

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies : Implications for cancer risk stratification and biomarker sampling. / Shah, Rajal B.; Bentley, James; Jeffery, Zach; Demarzo, Angelo Michael.

In: Human Pathology, Vol. 46, No. 5, 01.05.2015, p. 698-706.

Research output: Contribution to journalArticle

@article{3f5ba94d5a7b4affbf9ec9642ce33e79,
title = "Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: Implications for cancer risk stratification and biomarker sampling",
abstract = "ERG and PTEN biomarkers are increasingly being analyzed on prostate core biopsies (NBXs); ERG as a marker of clonality and number of separately arising tumor foci and PTEN for prognostic information. Yet, in patients with multiple biopsy cores positive for cancer (PCa), there is no standardized approach for interrogation of these biomarkers in terms of the number of positive cores to evaluate. A total of 194 NBX cases containing more than one positive core with cancer were evaluated for ERG overexpression and PTEN loss by immunostaining (immunohistochemistry) of all positive cores. ERG overexpression or PTEN loss in at least one cancer core was present in 111 (57{\%}) and 69 (36{\%}) cases respectively. ERG overexpression was significantly associated with PTEN loss (P",
keywords = "Biomarkers, ERG, Heterogeneity, Prostate cancer, Prostate needle biopsy, PTEN",
author = "Shah, {Rajal B.} and James Bentley and Zach Jeffery and Demarzo, {Angelo Michael}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.humpath.2015.01.008",
language = "English (US)",
volume = "46",
pages = "698--706",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies

T2 - Implications for cancer risk stratification and biomarker sampling

AU - Shah, Rajal B.

AU - Bentley, James

AU - Jeffery, Zach

AU - Demarzo, Angelo Michael

PY - 2015/5/1

Y1 - 2015/5/1

N2 - ERG and PTEN biomarkers are increasingly being analyzed on prostate core biopsies (NBXs); ERG as a marker of clonality and number of separately arising tumor foci and PTEN for prognostic information. Yet, in patients with multiple biopsy cores positive for cancer (PCa), there is no standardized approach for interrogation of these biomarkers in terms of the number of positive cores to evaluate. A total of 194 NBX cases containing more than one positive core with cancer were evaluated for ERG overexpression and PTEN loss by immunostaining (immunohistochemistry) of all positive cores. ERG overexpression or PTEN loss in at least one cancer core was present in 111 (57%) and 69 (36%) cases respectively. ERG overexpression was significantly associated with PTEN loss (P

AB - ERG and PTEN biomarkers are increasingly being analyzed on prostate core biopsies (NBXs); ERG as a marker of clonality and number of separately arising tumor foci and PTEN for prognostic information. Yet, in patients with multiple biopsy cores positive for cancer (PCa), there is no standardized approach for interrogation of these biomarkers in terms of the number of positive cores to evaluate. A total of 194 NBX cases containing more than one positive core with cancer were evaluated for ERG overexpression and PTEN loss by immunostaining (immunohistochemistry) of all positive cores. ERG overexpression or PTEN loss in at least one cancer core was present in 111 (57%) and 69 (36%) cases respectively. ERG overexpression was significantly associated with PTEN loss (P

KW - Biomarkers

KW - ERG

KW - Heterogeneity

KW - Prostate cancer

KW - Prostate needle biopsy

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=84930985267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930985267&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.01.008

DO - 10.1016/j.humpath.2015.01.008

M3 - Article

C2 - 25724568

AN - SCOPUS:84930985267

VL - 46

SP - 698

EP - 706

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 5

ER -